PT  - JOURNAL ARTICLE
AU  - Leslie Cho
TI  - A practical approach to the cholesterol guidelines and ASCVD prevention
AID  - 10.3949/ccjm.87.s1.02
DP  - 2020 May 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 15--20
VI  - 87
IP  - 5 suppl 1
4099  - http://www.ccjm.org/content/87/5_suppl_1/15.short
4100  - http://www.ccjm.org/content/87/5_suppl_1/15.full
SO  - Cleve Clin J Med2020 May 01; 87
AB  - Lifestyle factors remain the bedrock of atherosclerotic cardiovascular disease (ASCVD) prevention. Statins remain the first-line therapy for primary and secondary prevention of ASCVD. Physicians are encouraged to discuss the risks and benefits of statins with patients before beginning therapy. Nonstatins and proprotein convertase subtilisin-kexin type 9 inhibitors are recommended for secondary prevention in patients with clinical ASCVD. For patients at intermediate risk of ASCVD, new risk-enhancing factors, including chronic inflammatory conditions and ethnicity, should be considered to better risk stratify these patients.